Toripalimab plus anlotinib in patients with recurrent or metastatic nasopharyngeal carcinoma: A multicenter, single-arm phase 2 trial (TORAL).

Cell Rep Med · 2024 · PMC11722102 · PMID 39615484

Europe PMC DOI

hedged sentence

0.1590

closest p · 3.2× alpha

0.1590

boldest claim

The sentences

showed a trendp = 0.159not close (p > 0.1)

Interestingly, C1-negative patients showed a trend for a higher ORR (negative, 57.1% [8/14] vs. positive, 36.7% [6/21], p = 0.159) ( Table S7 ).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.